Found: 74
Select item for more details and to access through your institution.
Review: Improving Outcomes for Patients with Burkitt Lymphoma and HIV.
- Published in:
- AIDS Patient Care & STDs, 2008, v. 22, n. 3, p. 175, doi. 10.1089/apc.2007.0124
- By:
- Publication type:
- Article
Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 11, p. 1294, doi. 10.1002/cpdd.1153
- By:
- Publication type:
- Article
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.
- Published in:
- Kidney International, 2015, v. 87, n. 5, p. 1061, doi. 10.1038/ki.2014.423
- By:
- Publication type:
- Article
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single‐agent ibrutinib in patients with chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2019, v. 186, n. 1, p. 184, doi. 10.1111/bjh.15791
- By:
- Publication type:
- Article
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 5, p. 961, doi. 10.1111/bjh.15666
- By:
- Publication type:
- Article
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 4, p. 504, doi. 10.1111/bjh.15421
- By:
- Publication type:
- Article
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 2, p. 286, doi. 10.1111/bjh.14660
- By:
- Publication type:
- Article
Outcomes in CLL patients with NOTCH1 regulatory pathway mutations.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 6, p. E187, doi. 10.1002/ajh.26140
- By:
- Publication type:
- Article
Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL.
- Published in:
- Nature Communications, 2019, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41467-019-09645-5
- By:
- Publication type:
- Article
From the Mundane to the Absurd.
- Published in:
- Clinical Advances in Hematology & Oncology, 2023, v. 21, n. 9, p. 462
- By:
- Publication type:
- Article
I Wish I Knew . . .
- Published in:
- Clinical Advances in Hematology & Oncology, 2023, v. 21, n. 6, p. 275
- By:
- Publication type:
- Article
Informed Consent?
- Published in:
- Clinical Advances in Hematology & Oncology, 2023, v. 21, n. 4, p. 163
- By:
- Publication type:
- Article
Too Much?
- Published in:
- Clinical Advances in Hematology & Oncology, 2023, v. 21, n. 2, p. 58
- By:
- Publication type:
- Article
The Third Tier.
- Published in:
- Clinical Advances in Hematology & Oncology, 2022, v. 20, n. 12, p. 691
- By:
- Publication type:
- Article
There Has to Be a God ...
- Published in:
- Clinical Advances in Hematology & Oncology, 2022, v. 20, n. 10, p. 586
- By:
- Publication type:
- Article
I Think the FDA Got It Wrong ...
- Published in:
- Clinical Advances in Hematology & Oncology, 2022, v. 20, p. 474
- By:
- Publication type:
- Article
Debate, Argument, or Discussion?
- Published in:
- Clinical Advances in Hematology & Oncology, 2022, v. 20, n. 6, p. 347
- By:
- Publication type:
- Article
COVID-19 Vaccine Development.
- Published in:
- Clinical Advances in Hematology & Oncology, 2022, v. 20, n. 4, p. 195
- By:
- Publication type:
- Article
An Open Letter to Dr Fauci.
- Published in:
- Clinical Advances in Hematology & Oncology, 2022, v. 20, n. 2, p. 67
- By:
- Publication type:
- Article
To Boost or Not to Boost?
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, n. 11, p. 670
- By:
- Publication type:
- Article
Now for Something Completely Different.
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, n. 9, p. 542
- By:
- Publication type:
- Article
The Magnetic Appeal of Vaccination.
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, n. 7, p. 414
- By:
- Publication type:
- Article
The Too-Typical Clinical Conundrum.
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, n. 5, p. 272
- By:
- Publication type:
- Article
Should Venetoclax Be Used With or Without Anti-CD20 Therapy for CLL?
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, n. 4, p. 209
- By:
- Publication type:
- Article
It's the Path that Matters.
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, n. 3, p. 128
- By:
- Publication type:
- Article
One Step Closer to the End of COVID.
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, n. 1, p. 8
- By:
- Publication type:
- Article
An Optimist or a Realist?
- Published in:
- Clinical Advances in Hematology & Oncology, 2020, v. 18, n. 9, p. 503
- By:
- Publication type:
- Article
When Fast Means Faulty.
- Published in:
- Clinical Advances in Hematology & Oncology, 2020, v. 18, n. 7, p. 366
- By:
- Publication type:
- Article
Outside of Our Comfort Zone.
- Published in:
- Clinical Advances in Hematology & Oncology, 2020, v. 18, n. 5, p. 238
- By:
- Publication type:
- Article
Highlights in B-Cell Malignancies From the 61st American Society of Hematology Annual Meeting: Commentary.
- Published in:
- Clinical Advances in Hematology & Oncology, 2020, v. 18, p. 24
- By:
- Publication type:
- Article
Highlights in B-Cell Malignancies From the 61st American Society of Hematology Annual Meeting: Commentary.
- Published in:
- Clinical Advances in Hematology & Oncology, 2020, v. 18, p. 24
- By:
- Publication type:
- Article
Arbitrary vs Rational Treatment.
- Published in:
- Clinical Advances in Hematology & Oncology, 2020, v. 18, n. 2, p. 73
- By:
- Publication type:
- Article
Helping More Smokers to Quit.
- Published in:
- Clinical Advances in Hematology & Oncology, 2019, v. 17, n. 12, p. 648
- By:
- Publication type:
- Article
How Biosimilars Affect Health Care.
- Published in:
- Clinical Advances in Hematology & Oncology, 2019, v. 17, n. 10, p. 530
- By:
- Publication type:
- Article
Precise vs Imprecise Medicine.
- Published in:
- Clinical Advances in Hematology & Oncology, 2019, v. 17, n. 8, p. 418
- By:
- Publication type:
- Article
The Median Isn't the Message.
- Published in:
- Clinical Advances in Hematology & Oncology, 2019, v. 17, n. 6, p. 314
- By:
- Publication type:
- Article
Building a Better FDA.
- Published in:
- Clinical Advances in Hematology & Oncology, 2019, v. 17, n. 4, p. 194
- By:
- Publication type:
- Article
Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine- and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 6, p. E36, doi. 10.3816/CLM.2009.n.098
- By:
- Publication type:
- Article
Durable Complete Remissions in HIV-Associated Hodgkin Lymphoma After Treatment with Only One Cycle of Chemotherapy Complicated by Sepsis.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 3, p. 247, doi. 10.3816/CLM.2009.n.049
- By:
- Publication type:
- Article
Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.720704
- By:
- Publication type:
- Article
Long-Term Follow-Up of R-CHOP With Bevacizumab as Initial Therapy for Mantle Cell Lymphoma: Clinical and Correlative Results.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Pralatrexate is an effective treatment for relapsed transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup Efficacy Analysis From the PROPEL Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2012, v. 12, n. 4, p. 238, doi. 10.1016/j.clml.2012.01.010
- By:
- Publication type:
- Article
CD39 Expression on T Lymphocytes Correlates With Severity of Disease in Patients With Chronic Lymphocytic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 4, p. 367, doi. 10.1016/j.clml.2011.06.005
- By:
- Publication type:
- Article
Epratuzumab in non-Hodgkin's lymphomas.
- Published in:
- 2004
- By:
- Publication type:
- journal article
FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Subsequent therapy can be administered after tositumomab and iodine I‐131 tositumomab for non‐Hodgkin lymphoma.
- Published in:
- Cancer (0008543X), 2006, v. 106, n. 3, p. 616
- By:
- Publication type:
- Article
SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Proteasome inhibition with bortezomib: A new therapeutic strategy for non-Hodgkin's lymphoma.
- Published in:
- International Journal of Cancer, 2006, v. 119, n. 5, p. 971, doi. 10.1002/ijc.21805
- By:
- Publication type:
- Article